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Abstract 
Purpose: To investigate the probable antihypertensive effects of Gastrodia elata Bl. extract (GEBE) in 
renovascular hypertensive rats as well as the mechanism involved in blood pressure reduction. 
Methods: The two-kidney one-clip (2K1C) Goldblatt model of renovascular hypertension was used in 
Wistar rats. The 2K1C group rats were treated with captopril (40 mg/kg/day), low-dose GEBE (150 
mg/kg/day) and high-dose of GEBE (300 mg/kg/day) for 6 weeks by intragastric administration. Systolic 
(SBP) and diastolic blood pressure (DBP) were measured by the tail-cuff method. Urine creatinine and 
urea levels of the rats were measured by enzyme-linked immunosorbent assay (ELISA). Superoxide 
dismutase (SOD) and malondialdehyde (MDA) levels were also evaluated. 
Results: In the captopril- and GEBE-treated groups, blood pressure decreased progressively over the 
course of the 6-week treatment period compared with that of the untreated (control) rats (p < 0.01). 
High-dose GEBE also significantly increased plasma SOD activity but decreased plasma MDA 
concentration (p < 0.05). Renal function improved following captopril and GEBE (300 mg/kg/day) 
treatment (p < 0.01).  
Conclusion: The results suggest that GEBE probably exerts an antihypertensive effect by inhibiting 
endothelin (ET)-converting enzyme and via its antioxidant activity. 
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Hypertension is the most common risk factor for 
myocardial infarction, stroke, heart failure, 
arterial fibrillation, aortic dissection and 
peripheral arterial diseases. It is 
among the most common chronic illnesses in the 
world [1,2] and remains the leading cause of 
death worldwide and one of the world’s greatest 
public health problems. Although many new 
antihypertensive drugs with improved efficacy 
have been introduced to the market, they still 
possess serious side effects. On the one hand, 
nutrition and physical exercises are gaining more 
importance in the treatment of hypertension. On 
the other hand, attention has recently been 
focused on herbal and mineral preparations 
which are traditionally used as potential 
therapeutic agents in the prevention and 
management of cardiovascular diseases. 
 
Of the various experimental or genetic models of 
hypertension, the Goldblatt chronic two-kidney, 
one-cliphypertension (2K1C) is a classical model 
of renovascular angiotensin-II-dependent 
hypertension. Experimental model of renal 
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(Goldblatt) hypertension is one of the widely 
used models for the study of pathophysiology of 
hypertension and antihypertensive drugs [3,4]. 
The fact that the rennin-angiotensin system 
(RAS) contributes critically to the 
pathophysiology of 2K1C Goldblatt hypertension 
is well established [5]. The 2K1C model, which 
exhibits a transient increase in the activity of 
RAS and a sustained rise in blood pressure, has 
been described as very close to human mature 
hypertension [6,7]. Thus, hypertension in this 
model is primarily the result of an augmented 
total peripheral resistance and, in mild cases of 
renal artery stenosis, bilateral reduction in renal-
clearance function [8]. These physiological 
abnormalities are principally the result of a 
considerable increase in tissue and circulating 
levels, and direct actions of Ang-II [9]. Evidence 
shows that as the condition advances, the role of 
Ang-II in maintaining hypertension subsides, and 
other mediators become more effective in 
determining the levelof blood pressure [10]. 
 
To the best of our knowledge, there is no report 
on the anti-hypertensive effect of GEBE and the 
information regarding to the mechanism of GEBE 
against hypertension is very scarce. For these 
reasons, we describe, in the present paper, the 
anti-hypertensive effects of GEBE, together with 
changes in biological parameters such as SOD 
activity and MDA level, following the 





Collection and extraction of plant material 
 
The herbal material, Gastrodia elata Bl. was 
collected from Guilin City, Guangxi Province in 
China in May 2016. Taxonomic identification of 
the plant was performed by a taxonomist, 
Professor Ping Wang of Department of 
Pharmacy of Guizhou University, Guiyang, 
China. A voucher specimen (no. GEBE 
201605002) was deposited in the herbarium of 
College of Pharmacy, Guizhou University, China 
for future reference.  
 
The leaves of Gastrodia elata Bl. were dried by 
an oven and decocted in water at 60 ℃ for three 
times, each time for 1 h. Then the extract was 
first dried in an oven at 80 oC and then freeze-
dried to obtain GEBE. 
 
Induction of renovascular hypertension (two-
kidney, one-clip model) 
 
Goldblatt 2K1C model of hypertension was 
induced according to the procedure described by 
Umar et al [11]. Briefly, the rats were 
anesthetized with sodium pentobarbital (50 
mg/kg, intraperitoneally). The left renal artery 
was exposed by retroperitoneal flank incision and 
dissected free of the renal vein and connective 
tissue. A silver clip with a lumen of 0.22 mm was 
placed around the artery for partial occlusion; in 
sham operations, the artery was not clipped. 
After 6 weeks the systolic blood pressure (SBP) 
was measured using the tail-cuff method in 
conscious rats. Only hypertensive rats (SBP 
above 150 mm Hg) were used in the 
experiments. 
 
Animal groups  
 
The mice were randomly divided into four groups 
as follows: (1) sham-operated control group 
(served as negative control) (n = 8); (2) an 
untreated model group ( n = 8); (3) rats treated 
with captopril (40 mg/kg/day) group ( n = 8); (4) 
rats treated with low-dose of GEBE (GEBE-L,150 
mg/kg/day) ( n = 8), and rats treated with high-
dose of GEBE (GEBE-H, 300 mg/kg/day). Rats 
were treated for 6 weeks with daily oral 
administration of the products or the same 
volume of vehicle (0.9 % saline) (groups 1 and 
2). Doses of GEBE were chosen with reference 
to doses commonly used in human and doses 
used in previous experiments. All rats were 
weighed and their blood pressure measured 
once weekly for 4 weeks. Drugs were dissolved 
in water, and administered using a 5-ml syringe 
with a 4-cm long gavage needle through the 
mouth to the mouth once daily for 3 weeks. The 
animal experiment was approved by the Animal 
Care and Use Committee of Guizhou University 
(approval ref no. 20100405) and was carried out 
in compliance with the Directive 2010/63/EU on 
the handling of animals used for scientific 
purposes [12]. 
 
Measurement of blood pressure 
 
Systolic (SBP) and diastolic blood pressure 
(DBP) were measured by the tail-cuff method 
(BP-6 noninvasive Electro-Sphygmomanometer, 
Chengdu Taimeng  Science and Technology, 
Chengdu, PR China) in awaken rats. The mean 
of three consecutive readings was taken. The 
arterial systolic and diastolic blood pressure was 
measured at the weekend and continuous 
measurement was carried out three times as the 
average blood pressure for weeks. 
 
Assessment of renal function 
 
At the last week of the experiment, the animals 
were placed in individual metabolic cages and 
acclimatized for two consecutive days before a 
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24-h urine collection. Creatinine and urea were 
measured with a commercial enzyme-linked 
immunosorbent assay (Nanjing Institute of 
biological engineering, China) as described by 
the manufacturer. 
 
Determination of serum SOD activity and lipid 
peroxide level (MDA) 
 
Serum superoxide dismutase (SOD) activity and 
the malondialdehyde (MDA) level were 
determined according to the instructions in the kit 





Data are presented as mean ± standard 
deviation (SD), and were analyzed by one-way 
ANOVA followed by Tukey’s multiple comparison 
using SPSS 16.0 software for Windows. 
Differences were considered statistically 




Effect of GEBE on blood pressure of 2K1C 
hypertensive rats 
 
Untreated (model) renovascular hypertensive 
rats had markedly higher SBP and DBP than the 
sham-operated rats (p < 0.01). This hypertension 
was stable over 6 weeks of the experiment. In 
the captopril- and GEBE treated groups, the 
blood pressure decreased progressively over the 
course of the 6 weeks treatment compared with 
that of the untreated (model) rats (p < 0.01, 
Table 1). 
 
Table 1: Effect of GEBE on the blood pressure of 







Normal  - 142.3±6.2** 76.7±2.5** 
Control - 213.5±8.1 110.2±3.4 
Captopril 40 148.4±5.6** 80.5±3.2** 
GEBE-L 150 172.1±6.4* 98.3±6.1 
GEBE-H 300 153.2±4.3** 82.2±4.3** 
*P < 0.05 and **p < 0.01 versus control group; GEBE-L: 
low dose of GEBE (150 mg/kg/day); GEBE-H: high 
dose of GEBE (150 mg/kg/day) 
 
Effect of GEBE on renal dysfunction in 2K1C 
hypertensive rats 
 
The levels of blood urea nitrogen (BUN) and 
serum creatinine (Scr) were significantly higher in 
the untreated model group compared to the other 
group (p < 0.05). Both GEBE-L and GEBE-H 
were able to decrease the serum BUN and Scr 
levels (p < 0.01), respectively (Table 2). 
 










Normal - 45.3±4.6** 31±4.1** 
Control - 83.4±6.2 63.6±5.8 
Captopril 40 47±5.1** 45±7.6** 
GEBE-L 150 69±7.6 53±3.7 
GEBE-H 300 52±4.8** 37±3.5** 
*P < 0.05 and **p < 0.01 versus control group. GEBE-L: 
low dose of GEBE (150 mg/kg/day); GEBE-H: high 
dose of GEBE (150 mg/kg/day) 
 
Effect of GEBE on antioxidant status in 2K1C 
hypertensive rats 
 
The plasma SOD activity in the untreated control 
group was significantly lower than that in the 
sham-operated group. The SOD activity of the 
GEBE and captopril treated groups were 
significantly higher than that in the untreated 
control group (p < 0.01). The GEBE and 
captopril-treated groups showed significantly 
lower MDA level (p < 0.05) than the untreated 
model group (Table 3). 
 










Normal - 124.5±8.5** 4.7±1.2** 
Control - 85.9±6.4 13.6±3.4 
Captopril 40 117.6±6.7** 7.4±2.3* 
GEBE-L 150 98.4±5.9* 6.5±2.7* 
GEBE-H 300 118.7±6.6** 5.2±3.6* 
*P < 0.05 and **p < 0.01 versus control group. GEBE-L: 
low dose of GEBE (150 mg/kg/day); GEBE-H: high 




The 2K1C renovascular hypertension is a classic 
animal model of renin-dependent hypertension, 
which is considered to be similar to human renal 
hypertension. The 2K1C hypertension is an 
angiotensin-II (Ang-II) dependent model of 
hypertension where increased plasma and 
intrarenal AngII concentrations [13,14], enhanced 
production and systemic delivery of Ang-II by the 
clipped kidney, form the basic endocrine 
disturbance [15]. 
 
The endothelin (ET) system and RAAS are two 
of the most potent vasopressor mechanisms 
identified to date and in conditions where both 
systems are activated, their interrelationships 
have been proposed to contribute to the 
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development of hypertension [16]. Previous 
reports showed that blood pressure regulation is 
dependent on the relationship between the ET 
system and RAAS [17]. The active component of 
the RAAS is Ang-II, which is a potent 
vasoconstrictor and the mechanism of RAAS-
induced hypertension has generally been 
attributed to the direct vasoconstrictor effects of 
Ang-II and the mineralocorticoid effects of 
aldosterone. Ang-II can also elevate blood 
pressure by augmenting noradrenaline release 
from sympathetic nerve endings in the 
vasculature [18] by increasing secretion of potent 
vasoconstrictor ET-1. 
 
A recent hypothesis pointed out a possible role of 
oxidative stress as a key player in the 
pathogenesis of insulin resistance, cell 
dysfunction, and hypertension [19] and many 
mechanisms have been implicated in processes 
underlying oxidative stress-mediated 
hypertension. The relationship between the 
development of hypertension and the increased 
bioavailability of ROS or decreased antioxidant 
capacity, or both, have been demonstrated in 
many experimental models of hypertension as 
well as in human hypertension [20]. These 
findings are based, in general, on increased 
levels of biomarkers of lipid peroxidation and 
oxidative stress [21]. 
 
Research data suggest that oxidative damage 
and proinflammatory processes may precede 
full-blown hypertension [22]. As 
malondialdehydes (MDA) are a class of terminal 
lipid peroxidation metabolites, determination of 
their content can directly reflect lipid peroxidation 
levels. On the other hand, SOD is a natural 
antioxidant enzyme which can remove 
superoxide anion radicals in vivo to maintain the 
production of free radicals in the body and clear 
the dynamic equilibrium of a metal enzyme. 
Therefore, protection of the endothelial function 
and reduction of free radical damage in the 
treatment and prevention of hypertensive target 
organ damage can have a far-reaching 
significance.  
 
The results obtained suggest that GEBE may 
play a key role in scavenging OFR, thus causing 
anti-oxidation effects and can clear free radicals 
from the system, which in turn effectively 
improved the endothelial lipid oxidative damage 
and high blood pressure to the same extent as 






This study demonstrate the significant 
antihypertensive effect of GEBE which is 
achieved by inhibiting endothelin-converting 
enzyme and via its antioxidant activity. Thus, 
GEBE has the potential to be developed as a 
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